Note 16 - Subsequent Event

12 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Subsequent Events [Text Block]

1

6

.

Subsequent Event

In

February 2019,

we acquired the AZEDRA manufacturing assets for

$8.0

million cash consideration and entered into a sublease agreement for the radiopharmaceutical manufacturing facility located in Somerset, New Jersey. The Somerset site serves as the launch facility for AZEDRA and will also provide manufacturing support for the Company’s development stage radiopharmaceuticals, including

1095.

We also secured the long-term supply of iodine necessary for the production of both AZEDRA and

1095.

The production of AZEDRA uses a proprietary Ultratrace

®

process which concentrates the MIBG targeted radiolytic activity by eliminating non-therapeutic “cold” MIBG molecules, giving AZEDRA a uniquely high specific activity. We are still evaluating the accounting implications of this transaction.